MedTrace Logo

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

NCT05336409 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-12-18

No results posted yet for this study

Summary

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

Conditions

  • R/R CD19-Positive B-Cell Malignancies
  • Indolent Non-Hodgkin Lymphoma
  • Aggressive Non-Hodgkin Lymphoma

Interventions

DRUG

Lymphodepleting Chemotherapy

LDC as prespecified in the protocol.

BIOLOGICAL

CNTY-101

CNTY-101 cells for intravenous (IV) infusion

BIOLOGICAL

IL-2

IL-2 subcutaneous (SQ) injection

Sponsors & Collaborators

  • Century Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2025-07-01
Completion
2025-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05336409 on ClinicalTrials.gov